Abstract
Letters6 September 2011Off-Label Use of Recombinant Factor VIIaAnne Phillips, MD, Vice President, Clinical, Medical and Regulatory AffairsAnne Phillips, MD, Vice President, Clinical, Medical and Regulatory AffairsFrom Novo Nordisk, Princeton, NJ 08540.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-5-201109060-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In the 19 April 2011 issue, Logan and colleagues (1) and Yank and colleagues (2) presented summaries of their assessment of use of recombinant factor VIIa (rFVIIa), sponsored by the Agency for Healthcare Research and Quality (AHRQ) (3). Novo Nordisk is concerned that these articles do not put rFVIIa use into proper context. Most rFVIIa is used in patients with hemophilia with inhibitors in the outpatient setting.In 1972, Ulla Hedner discovered that coagulation factor VII was able to bypass factor VIII/IX–mediated clotting in patients with hemophilia complicated by alloantibodies. Because of the limited availability of plasma ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
